ReviewFrontiers in immunology2021
The Key Role of NAD
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.Signal transduction and targeted therapy · 2026Review
- Differential NAD + availability may drive asymmetric SIRT7 activity in tumor and immune cells.Molecular biology reports · 2026Review
- Why is the tumor microenvironment disordered by NADH/NADRedox biology · 2026Review
- Article
- cGAS-STING signaling pathway in MASLD and liver fibrosis.Journal of molecular medicine (Berlin, Germany) · 2026Review
- Regulating the regulators via targeting CD38 in the tumor microenvironment.Frontiers in immunology · 2026Review
- Research on the interactive mechanisms between mitochondrial variations and immune responses in gliomas based on integrated visualization analysis.Discover oncology · 2025Review
- Beneficial effect of resveratrol on T cell oxidative metabolism and anti-tumor function is conditioned by priorMolecular therapy. Methods & clinical development · 2025Article
- Emerging strategies, applications and challenges of targeting NADNature aging · 2025Review
- Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer.Cancer research · 2025Article
- NAD+ Boosting Through NRH Supplementation Enhances Treatment Efficacy in EOC In Vitro.International journal of molecular sciences · 2025Article
- Unveiling the Molecular Mechanisms of Glioblastoma through an Integrated Network-Based Approach.Biomedicines · 2024Article
- Nicotinamide: Bright Potential in Glaucoma Management.Biomedicines · 2024Review
- Evolving roles of CD38 metabolism in solid tumour microenvironment.British journal of cancer · 2023Review
- Tryptophan and its metabolites in normal physiology and cancer etiology.The FEBS journal · 2023Review
- A prognostic NAD+ metabolism-related gene signature for predicting response to immune checkpoint inhibitor in glioma.Frontiers in oncology · 2023Article
- Review
- Review
- Article
- Dihydronicotinamide Riboside Is a Potent NADFrontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nicotinamide adenine dinucleotide (NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.